Letter From The Editor: Important Information On PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
PharmAsia News will cease publication as a stand-alone product at the end of June/early July. However, the on-the-ground team of journalists who produce PAN will all continue to provide the same in-depth insight, news, and analysis as previously, and this content will be made available through Informa’s updated Scrip platform. All PAN subscribers will receive Scrip from early July, and Asia-Pacific regulatory content will be available through the expanded Pink Sheet and its new platform.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.